Cat. No. 4530
Alternative Name: Arundic acid
Chemical Name: (2R)-2-Propyloctanoic acid
Biological ActivityInhibits S-100β synthesis in activated cultured astrocytes. Prevents delayed infarct expansion 24 hours after permanent middle cerebral artery occlusion (pMCAO) in rats; also exhibits neuroprotective effects in mouse models of Parkinson's disease and Alzheimer's disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Tateishi et al (2002) Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J.Cereb.Blood Flow Metab. 22 723. PMID: 12045671.
Kato et al (2004) Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res. 1030 66. PMID: 15567338.
Mori et al (2006) Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J.Pharmacol.Exp.Ther. 318 571. PMID: 16709678.
If you know of a relevant citation for this product please let us know.
Keywords: ONO 2506, supplier, ONO2506, S100B, bbb, blood, brain, barrier, stroke, neuroprotective, Alzheimer's, parkinson's, disease, astrocytes, astrocytic, arundic, acid, parkinsons, alzheimers
Find multiple products by catalog number
New Products in this Area
Inhibitor of phosphatidylcholine transfer protein (PC-TP)Hydroxychloroquine sulfate
Autophagy inhibitor; also TLR9 inhibitorTC-G 1005
Potent and selective TGR5 agonistNSC 617145
Werner syndrome helicase (WRN) inhibitor
December 15 - 17, 2015